Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 - Promising Drug Pipeline / High Cost of Therapy / Personalized Medicine

Nov 12, 2015, 20:10 ET from Research and Markets

DUBLIN, Nov. 12, 2015 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019" report to their offering.

The global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019.

The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer. The report includes a discussion of the key vendors operating in this market.

The non-small cell lung cancer therapeutics market in China grew exponentially in 2014. The markets in Australia, India, and Japan are expected to witness considerable growth during the forecast period.

According to the report, current therapies available to treat non-small cell lung cancer do not provide a permanent cure, and approaches such as non-selective cytotoxic chemotherapy tend to cause toxicity in patients.

Further, the report states that the increase in personalized therapies will lead to the fragmentation of the global non-small cell lung cancer market, thus presenting a major threat to this market.

Key vendors

  • AstraZeneca
  • Celgene
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Pfizer

Other prominent vendors

  • Abbvie
  • Aetna
  • Agennix
  • Amgen
  • BetaPharma
  • Bionumerik Pharmaceuticals
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CBT Pharma
  • Celldex Therapeutics
  • Dainippon Pharma
  • Eisai Pharmaceuticals
  • GlaxoSmithKline
  • Helsinn
  • IMClone Systems
  • IsisPharma
  • Kadmon
  • Kyowa Hakko Kirin
  • MabVax Therapeutics
  • Merck
  • Novartis
  • OncoGenex
  • OSI Pharmaceuticals
  • Peregrine
  • Pierre Fabre
  • Qiagen
  • Sanofi
  • Synta Pharmaceuticals
  • Teva Pharmaceuticals

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Product profiles

Part 05: Introduction

Part 06: Disease overview

Part 07: Pipeline portfolio

Part 08: Market landscape

Part 09: Market segmentation by molecule type

Part 10: Market segmentation by route of administration

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

Part 19: Appendix

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


SOURCE Research and Markets